O-(beta-hydroxyethyl)-rutosides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications.
Cesarone
Maria Rosaria
MR
Belcaro
Gianni
G
Grossi
Maria Giovanna
MG
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006896:Hydroxyethylrutoside / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008833:Microcirculation / Q000187:drug effects; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D014690:Venous Pressure / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002317:Cardiovascular Agents; D006896:Hydroxyethylrutoside; C005865:troxerutin